Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Alnylam Pharmaceuticals, Inc. (ALNY) - free report >>
Bristol Myers Squibb Company (BMY) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alnylam Pharmaceuticals, Inc. (ALNY) - free report >>
Bristol Myers Squibb Company (BMY) - free report >>
Image: Bigstock
Alnylam (ALNY) Begins Phase I/II Study on Chronic HBV Drug
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that it has initiated a phase I/II study on one of its pipeline candidates, ALN-HBV, which is a subcutaneously administered experimental RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection.
The randomized, single-blind, placebo-controlled study is being conducted in three sequential parts. It will be initially conducted in normal healthy volunteers and then in chronic HBV patients. The primary objective of the study is to evaluate the safety and tolerability of single and multiple subcutaneous doses of ALN-HBV. The company expects to report initial data from the study in mid-2017.
We note that ALN-HBV is being developed utilizing the company's enhanced stabilization chemistry-GalNAc-siRNA conjugate delivery platform.
ALNYLAM PHARMA Price
ALNYLAM PHARMA Price | ALNYLAM PHARMA Quote
We are encouraged by the company’s progress with the candidate. Per the company’s press release, 2 billion people are infected with HBV across the world and 400 million people have become chronically infected. In the U.S. alone there are 1 to 2 million people chronically infected with HBV. Moreover, an estimated 1 million people die each year from HBV and its complications worldwide.
Considering that there exists a significant unmet need for drugs targeting chronically infected HBV patients, if developed successfully, ALN-HBV could gain an opportunity to cater to a large market.
Meanwhile, Alnylam has made substantial progress with its RNAi therapeutics pipeline. Presently, the two most advanced candidates at Alnylam are patisiran (phase III – familial amyloidotic polyneuropathy) and revusiran (phase III – familial amyloidotic cardiomyopathy). While Alnylam expects to report data from the APOLLO study on patisiran in mid-2017, data readout from the ENDEAVOUR study on revusiran is anticipated in early 2018.
Alnylam is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the healthcare sector include Innoviva, Inc. (INVA - Free Report) , Bristol-Myers Squibb Company (BMY - Free Report) and Pfizer Inc. (PFE - Free Report) . While Innoviva sports a Zacks Rank #1 (Strong Buy), Bristol-Myers and Pfizer carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>